The retinoblastoma tumor suppressor gene is a prototype for tumor suppressor genes. Its protein, pRB, is an integral protein that is disrupted in a vast majority of human tumors. Understanding the underlying mechanisms of pRB tumor suppression is, therefore, of critical importance. What is the molecular mechanism of pRB action? In various experimental settings, pRB can be shown to mediate cell cycle arrest, promote cellular differentiation, suppress apoptosis, repress transcription of some transcription factors (E2F) and activate transcription with others (myoD and C/EBP). These activities have been studied primarily in artificial assay systems and currently it is unclear which of these pRB properties are most important in-vivo. It is known that a large domain of pRB, the pocket, is necessary and sufficient for most of pRB's activities. Studies of chimeric mice pith RB -/- cells demonstrate that loss of pRB does not remove most aspects of cell cycle control. In such mice, RB -/- cells contribute to most tissues and have normal histology. We hypothesize, that pRB is not generally essential for cell cycle control but that it must have very specific roles relevant to tumorigenesis. Preliminary data from the Dyson laboratory suggests that maintenance of the genomic integrity of cells may be dependent upon pRB's ability to induce a cell cycle arrest in response to DNA damage. Recent findings also suggest that pRB's ability to promote differentiation correlates with tumorigenicity. This proposal will investigate the in-vivo significance of pRB pathways leading to cell cycle arrest in response to DNA damage and to cellular differentiation in pRB tumor suppression.
Specific Aim number 1: To identify the structural features important for pRB to induce cell cycle arrest in response to DNA damage and to promote cellular differentiation. The pRB-associated proteins essential to these two pathways will be identified.
Specific Aim number 2: To determine whether the ability of pRB to arrest cell cycle and promote cellular differentiation is important for pRB to act as a tumor suppressor in-vivo using the RB mutants generated in aim number 1 to disable these specific pathways.
Specific Aim number 3: To determine whether the deregulation of E2F dependent transcription is correlated with the tumorigenic potential of RB -/- cells in-vivo.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
1K08CA082163-01
Application #
2881535
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lohrey, Nancy
Project Start
1999-09-30
Project End
2004-09-29
Budget Start
1999-09-30
Budget End
2000-09-29
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Shirai, Katsuyuki; Chakravarti, Arnab (2011) Towards personalized therapy for patients with glioblastoma. Expert Rev Anticancer Ther 11:1935-44
Chakravarti, Arnab; Zhai, Gary; Suzuki, Yoshiyuki et al. (2004) The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22:1926-33
Chakravarti, Arnab; Chakladar, Abhijit; Delaney, Meaghan A et al. (2002) The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 62:4307-15
Chakravarti, Arnab; Loeffler, Jay S; Dyson, Nicholas J (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62:200-7
Chakravarti, Arnab; Noll, Elizabeth; Black, Peter McL et al. (2002) Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20:1063-8
Chakravarti, A; Delaney, M A; Noll, E et al. (2001) Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 7:2387-95